As suggested by several international guidelines, in patients with DME and a history of stroke or myocardial infarction it could be more prudent to use intravitreal CSc as first-line treatment rather than anti-VEGF agents [13,14,15,16,17,18,19]. The gene discussed is VEGFA; the disease is Stroke.